FortiHFy

Novartis AG (ADR) (NYSE: NVS) announced on Thursday the establishment of FortiHFy, short for Fortifying Heart Failure clinical evidence and patient quality of life. FortiHFy is an umbrella clinical program that consists of over 40 active or planned trials. The global clinical program will result in...